Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03531905 · ClinicalTrials.gov registry record · Phase 2
Bempedoic Acid + Ezetimibe Fixed-Dose Combination (FDC) Study in Patients With Type 2 Diabetes and Elevated LDL-C
A Phase 2 study, sponsored by Esperion Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 242
- Enrollment target
NCT03531905 is a Phase 2 study that has completed, run by Esperion Therapeutics. The registered enrollment target is 242 participants.
The verdict
NCT03531905, a Phase 2 study, has completed, sponsored by Esperion Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 242 participants
- Enrollment target
Study Summary
12 week study to assess the LDL-C lowering efficacy, other lipid and glycemic measures, and safety of bempedoic acid/ezetimibe FDC compared to ezetimibe and placebo in patients with type 2 diabetes (T2D) and elevated LDL-C
Interventions
- DRUG Placebo oral capsule
- DRUG Placebo Oral Tablet
- DRUG Bempedoic acid + Ezetimibe FDC Oral Tablet
- DRUG Ezetimibe 10 mg Oral Tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 242 participants |
| Start Date | 2018-05-09 |
| Est. Completion | 2019-06-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03531905
The ClinicalTrials.gov registry entry for NCT03531905 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 242 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Esperion Therapeutics, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo oral capsule is the first listed.
NCT03531905 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03531905 about?
NCT03531905 is a clinical study titled "Bempedoic Acid + Ezetimibe Fixed-Dose Combination (FDC) Study in Patients With Type 2 Diabetes and Elevated LDL-C". 12 week study to assess the LDL-C lowering efficacy, other lipid and glycemic measures, and safety of bempedoic acid/ezetimibe FDC compared to ezetimibe and placebo in patients with type 2 diabetes (T2D) and elevated LDL-C
What is the current status of trial NCT03531905?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 242 participants. The study started on 2018-05-09. Estimated completion is 2019-06-18.
What interventions are being tested in trial NCT03531905?
The interventions under investigation include: Placebo oral capsule (DRUG), Placebo Oral Tablet (DRUG), Bempedoic acid + Ezetimibe FDC Oral Tablet (DRUG), Ezetimibe 10 mg Oral Tablet (DRUG).
Who is sponsoring clinical trial NCT03531905?
This trial is sponsored by Esperion Therapeutics, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.